摘要
已上市的改善脑代谢药物主要包括麦角碱衍生物、γ-氨基丁酸衍生物、维生素B_(6)衍生物、神经肽类、吗啉类、激素类等,在临床应用时可能会发生不良反应。该文对脑代谢药物的不良反应问题,从药物联用、手性拆分异构体、优势药物晶型、共晶药物和纳米药物等适于药用新物质状态研究以降低不良反应角度进行综述,归纳了通过改变药物的固体物质状态改善其不良反应的研究方案,为获得不良反应小且更具有临床价值的新型药物研发提供新的研究思路。
The drugs used to improve brain metabolism mainly include ergotamine derivatives,GABA derivatives,vitamin B_(6) derivatives,neuropeptides,morpholines,hormones and other.However,these drugs may have adverse reactions during clinical application.This article focuses on the adverse effects of commonly used drugs for brain metabolism,and reviews the studies on the new state of pharmaceutical substances,such as drug combination,chiral resolution of isomers,crystal form of dominant drugs,co-crystal drugs and nanodrugs,with the aim of reducing adverse reactions.By summarizing the research on modifying the solid state of drugs to mitigate adverse reactions,this article provides new research insights for obtaining new drug with less adverse reaction and greater clinical value.
作者
王文文
贾艳潇
闫明
杨德智
高莉
张丽
吕扬
WANG Wenwen;JIA Yanxiao;YAN Ming;YANG Dezhi;GAO Li;ZHANG Li;LYU Yang(Beijing Key Laboratory of Polymorphic Drugs,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Key Laboratory of Uyghur Formula Studies,Xinjiang Uygur Autonomous Region Uygur Medicine Research Institute,Urumqi 830000,China)
出处
《医药导报》
北大核心
2025年第6期862-867,共6页
Herald of Medicine
基金
新疆维吾尔自治区重点实验室开放课题(2023D04065)
中国医学科学院医学与健康科技创新工程重大协同创新项目(2022-I2M-1-015)
山东省重点研发计划(2021ZDSYS26)
新疆维吾尔自治区2023年“天池英才”项目。
关键词
脑代谢药物
药品不良反应
适药新物态
晶型
共晶
Brain metabolism drugs
Adverse drugs effects
New state for pharmaceuticalsubstance
Polymorphicdrugs
Co-crystal drugs
